ArriVent GC granted 130,000 stock options

ArriVent BioPharma’s General Counsel, James Paul Kastenmayer, received a stock option grant reported on a Form 4.

Rhea-AI Filing Summary

ArriVent BioPharma’s General Counsel, James Paul Kastenmayer, received a stock option grant reported on a Form 4. He was awarded options covering 130,000 shares of common stock at an exercise price of $22.67 per share.

The option was granted on February 2, 2026. The underlying shares vest 25% on February 2, 2027, with the remaining 75% vesting in 36 equal monthly installments after that date, conditioned on his continued service. Following this grant, he beneficially owns 130,000 stock options directly.

Insider Trade Summary

Grant/Award: 130,000 shares

Grant/Award 1 txn

Insider Kastenmayer James Paul

Role General Counsel

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	130,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 130,000 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this option vest as to 25% on February 2, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ArriVent BioPharma (AVBP) report in this Form 4?

ArriVent BioPharma reported a stock option grant to its General Counsel. The filing shows 130,000 options awarded on February 2, 2026, each exercisable for one share of common stock at $22.67, subject to a multi-year vesting schedule tied to continued service.

Who is the insider in ArriVent BioPharma (AVBP)’s latest Form 4 filing?

The insider is James Paul Kastenmayer, General Counsel of ArriVent BioPharma. He is identified as an officer, not a director or 10% owner, and is the sole reporting person on this Form 4 covering a single stock option grant transaction.

How many stock options were granted to ArriVent BioPharma (AVBP)’s General Counsel?

James Paul Kastenmayer received 130,000 stock options. Each option represents the right to buy one share of ArriVent BioPharma common stock, bringing his total beneficially owned derivative securities to 130,000 options immediately after the reported grant transaction.

What is the exercise price of the ArriVent BioPharma (AVBP) stock options granted?

The stock options have a conversion or exercise price of $22.67 per share. This means the General Counsel can purchase ArriVent BioPharma common stock at $22.67 for each of the 130,000 options, once the respective portions of the grant have vested.

How do the ArriVent BioPharma (AVBP) options vest for the General Counsel?

The options vest over time, starting with 25% on February 2, 2027. The remaining 75% vests in 36 equal monthly installments afterward, and each vesting step requires the General Counsel to continue providing service through the applicable vesting date.

Are the ArriVent BioPharma (AVBP) options held directly or indirectly by the insider?

The Form 4 reports that all 130,000 stock options are held directly by the insider. The ownership form is marked as direct, and no footnotes indicate that the options are held through a trust, LLC, or other related entity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 08:39 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kastenmayer James Paul

(Last) (First) (Middle)

C/O ARRIVENT BIOPHARMA, INC.

18 CAMPUS BOULEVARD, SUITE 100

(Street)

NEWTOWN SQUARE PA 19073

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ArriVent BioPharma, Inc. [ AVBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$22.67	02/02/2026		A		130,000		(1)	02/02/2036	Common Stock	130,000	$0	130,000	D

Explanation of Responses:

1. The shares underlying this option vest as to 25% on February 2, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ James Paul Kastenmayer	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.